MDM2 and glioblastoma: Survival analysis did not show a distinct survival difference between molecular glioblastoma patients with or without MET, MDM2 or EGFR amplifications (logrank p = 0,997; p = 0,478; p = 0.181 respectively) (Fig. 4).